- Approximately 1,000 patients in the U.S. 12 years of age and older are now eligible for this one-time treatment- ZUG, Switzerland and BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics ...
ZUG, Switzerland and BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...
Exagamglogene autotemcel resulted in significant improvements in quality of life for patients with severe sickle cell disease or transfusion-dependent beta-thalassemia. Patients reported clinically ...
Please provide your email address to receive an email when new articles are posted on . Children with beta thalassemia achieved transfusion independence after being treated with exa-cel. Children with ...
On December 6, 2025, Vertex Pharmaceuticals Inc. (“Vertex”) announced data from several studies demonstrating the clinical benefits of CASGEVY ® (exagamglogene autotemcel), including, for the first ...
As more patients with sickle cell disease or β-thalassemia are treated with the gene-edited cellular drug exa-cel, there are more opportunities to test for potential off-target editing. The authors ...
A study assessing the real-world commercial roll-out of gene therapies for sickle cell disease and beta thalassemia offers lessons learned to inform best practices as manufacturers and medical centers ...
Exagamglogene autotemcel (exa-cel) significantly improved HRQOL in severe SCD patients, eliminating severe VOCs and hospitalizations in most cases. The CLIMB SCD-121 trial showed sustained ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results